FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079730922> ?p ?o ?g. }

• W2079730922 endingPage "1837" @default.
• W2079730922 startingPage "1832" @default.
• W2079730922 abstract "Phase II trial reports have suggested that the addition of bleomycin to the combination of cisplatin and ifosfamide may improve response rates and possible survival in squamous carcinoma of the cervix. This study prospectively evaluates the combination of bleomycin to this regimen in women with histologically proven advanced recurrent or persistent squamous cell carcinoma of the cervix.Eligible women were randomized to receive either cisplatin (50 mg/m(2)), ifosfamide (5 g/m(2) over 24 hours), and mesna (6 g/m(2) during ifosfamide infusion and the following 12 hours) (CI) versus bleomycin 30 units over 24 hours on day 1 followed by cisplatin (50 mg/m(2)), ifosfamide (5 g/m(2) over 24 hours), and mesna (6 g/m(2) during ifosfamide infusion and the following 12 hours) (CIB). Three hundred three women were enrolled onto this trial, of which 287 were assessable.There were no significant differences between CI and CIB with regard to response rates (32% v 31.2%, respectively), progression-free survival (PFS), or overall survival. PFS and survival were associated with initial performance status (PS). Patients with a PS of 0 experienced a lower rate of failure (P =.013) and a lower risk of death (P =.009) compared with patients with PS of 2. The most frequent grade 3/4 toxicities were leukopenia, neutropenia, anemia, thrombocytopenia, and nausea and vomiting. Neither regimen was associated with a significant increase in incidence of these toxicities.The CI regimen was virtually identical to CIB with regard to response rate, PFS, survival, and toxicity profile. Thus, the addition of bleomycin in the dose-schedule employed to cisplatin and ifosfamide did not improve outcome in patients with advanced cervical cancer." @default.
• W2079730922 created "2016-06-24" @default.
• W2079730922 creator A5009442045 @default.
• W2079730922 creator A5012517342 @default.
• W2079730922 creator A5017254635 @default.
• W2079730922 creator A5043502023 @default.
• W2079730922 creator A5061736280 @default.
• W2079730922 creator A5067774048 @default.
• W2079730922 creator A5071052216 @default.
• W2079730922 creator A5082212106 @default.
• W2079730922 date "2002-04-01" @default.
• W2079730922 modified "2023-10-16" @default.
• W2079730922 title "Randomized Trial of Cisplatin and Ifosfamide With or Without Bleomycin in Squamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study" @default.
• W2079730922 cites W1840778568 @default.
• W2079730922 cites W1932754573 @default.
• W2079730922 cites W1935824237 @default.
• W2079730922 cites W1966268410 @default.
• W2079730922 cites W1984354495 @default.
• W2079730922 cites W2021543666 @default.
• W2079730922 cites W2050060574 @default.
• W2079730922 cites W2076264206 @default.
• W2079730922 cites W2077469663 @default.
• W2079730922 cites W2083717566 @default.
• W2079730922 cites W2106516999 @default.
• W2079730922 cites W2151685860 @default.
• W2079730922 cites W2253411526 @default.
• W2079730922 cites W2255368071 @default.
• W2079730922 cites W2260425810 @default.
• W2079730922 cites W2314753133 @default.
• W2079730922 cites W2324392028 @default.
• W2079730922 cites W2328935341 @default.
• W2079730922 cites W2541820485 @default.
• W2079730922 cites W3147894994 @default.
• W2079730922 doi "https://doi.org/10.1200/jco.2002.07.045" @default.
• W2079730922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11919241" @default.
• W2079730922 hasPublicationYear "2002" @default.
• W2079730922 type Work @default.
• W2079730922 sameAs 2079730922 @default.
• W2079730922 citedByCount "104" @default.
• W2079730922 countsByYear W20797309222012 @default.
• W2079730922 countsByYear W20797309222013 @default.
• W2079730922 countsByYear W20797309222014 @default.
• W2079730922 countsByYear W20797309222015 @default.
• W2079730922 countsByYear W20797309222016 @default.
• W2079730922 countsByYear W20797309222017 @default.
• W2079730922 countsByYear W20797309222018 @default.
• W2079730922 countsByYear W20797309222019 @default.
• W2079730922 countsByYear W20797309222020 @default.
• W2079730922 countsByYear W20797309222021 @default.
• W2079730922 countsByYear W20797309222022 @default.
• W2079730922 countsByYear W20797309222023 @default.
• W2079730922 crossrefType "journal-article" @default.
• W2079730922 hasAuthorship W2079730922A5009442045 @default.
• W2079730922 hasAuthorship W2079730922A5012517342 @default.
• W2079730922 hasAuthorship W2079730922A5017254635 @default.
• W2079730922 hasAuthorship W2079730922A5043502023 @default.
• W2079730922 hasAuthorship W2079730922A5061736280 @default.
• W2079730922 hasAuthorship W2079730922A5067774048 @default.
• W2079730922 hasAuthorship W2079730922A5071052216 @default.
• W2079730922 hasAuthorship W2079730922A5082212106 @default.
• W2079730922 hasConcept C121608353 @default.
• W2079730922 hasConcept C126322002 @default.
• W2079730922 hasConcept C141071460 @default.
• W2079730922 hasConcept C143998085 @default.
• W2079730922 hasConcept C2776694085 @default.
• W2079730922 hasConcept C2776755627 @default.
• W2079730922 hasConcept C2777063308 @default.
• W2079730922 hasConcept C2777506904 @default.
• W2079730922 hasConcept C2777740455 @default.
• W2079730922 hasConcept C2778239845 @default.
• W2079730922 hasConcept C2778670039 @default.
• W2079730922 hasConcept C2780376820 @default.
• W2079730922 hasConcept C2780873365 @default.
• W2079730922 hasConcept C2781413609 @default.
• W2079730922 hasConcept C71924100 @default.
• W2079730922 hasConcept C90924648 @default.
• W2079730922 hasConceptScore W2079730922C121608353 @default.
• W2079730922 hasConceptScore W2079730922C126322002 @default.
• W2079730922 hasConceptScore W2079730922C141071460 @default.
• W2079730922 hasConceptScore W2079730922C143998085 @default.
• W2079730922 hasConceptScore W2079730922C2776694085 @default.
• W2079730922 hasConceptScore W2079730922C2776755627 @default.
• W2079730922 hasConceptScore W2079730922C2777063308 @default.
• W2079730922 hasConceptScore W2079730922C2777506904 @default.
• W2079730922 hasConceptScore W2079730922C2777740455 @default.
• W2079730922 hasConceptScore W2079730922C2778239845 @default.
• W2079730922 hasConceptScore W2079730922C2778670039 @default.
• W2079730922 hasConceptScore W2079730922C2780376820 @default.
• W2079730922 hasConceptScore W2079730922C2780873365 @default.
• W2079730922 hasConceptScore W2079730922C2781413609 @default.
• W2079730922 hasConceptScore W2079730922C71924100 @default.
• W2079730922 hasConceptScore W2079730922C90924648 @default.
• W2079730922 hasIssue "7" @default.
• W2079730922 hasLocation W20797309221 @default.
• W2079730922 hasLocation W20797309222 @default.
• W2079730922 hasOpenAccess W2079730922 @default.
• W2079730922 hasPrimaryLocation W20797309221 @default.
• W2079730922 hasRelatedWork W1966711911 @default.

• next